目的 探讨小儿咳喘灵颗粒联合头孢他啶治疗儿童支原体肺炎的临床疗效。方法 选取2021年8月—2023年8月北京市大兴区人民医院收治的116例支原体肺炎患儿，按随机数字表法将所有患儿分为对照组和治疗组，每组各58例。对照组静脉滴注注射用头孢他啶，50 mg/(kg∙次)，加入5%葡萄糖注射液100 mL中稀释后使用，2次/d。治疗组在对照组治疗基础上开水冲服小儿咳喘灵颗粒，患儿年龄≤2岁，1 g/次；2岁＜患儿年龄≤4岁，1.5 g/次；4岁＜患儿年龄≤7岁，2 g/次；7岁＜患儿年龄≤11岁，2.5 g/次；11岁＜患儿年龄≤14岁，3 g/次，3次/d。两组疗程7 d。观察两组临床疗效、主症消失时间、肺炎支原体IgM抗体（MP-IgM）转阴率；比较治疗前后两组全血血小板与淋巴细胞比值（PLR）、血清C反应蛋白（CRP）水平。结果 治疗后，治疗组总有效率是96.55%，显著高于对照组的86.21%（P＜0.05）。治疗过程中，治疗组发热、咳嗽、气喘、痰壅、肺部啰音消失时间显著短于对照组（P＜0.05）；治疗组MP-IgM转阴率是89.66%，显著高于对照组75.86%（P＜0.05）。治疗后，两组全血PLR和血清CRP水平低于同组治疗前（P＜0.05）；治疗后，治疗组全血PLR和血清CRP水平低于对照组（P＜0.05）。结论 小儿咳喘灵颗粒联合头孢他啶治疗儿童支原体肺炎具有较好的临床疗效，能有效控制支原体感染，抑制炎症反应，加速症状的缓解，值得临床推广应用。

Objective To explore the clinical efficacy of Xiao’er Kechuanling Granules combined with ceftazidime in treatment of mycoplasma pneumonia in children. Methods A total of 116 children with mycoplasma pneumonia admitted to Beijing Daxing District People’s Hospital from August 2021 to August 2023 were selected and divided into control group and treatment group according to random number table method, with 58 cases in each group. Patients in the control group were iv administered with Ceftazidime for injection, 50 mg/(kg∙time), diluted with 5% glucose injection 100 mL, twice daily. Patients in the treatment group were po administered with Xiao’er Kechuanling Granules on the basis of the control group, children ≤ 2 years old, 1 g/ time, children < 2 years old ≤ 4 years old, 1.5 g/ time, children < 4 years old ≤ 7 years old, 2 g/ time, children < 7 years old ≤ 11 years old, 2.5 g/ time, children < 11 years old ≤ 14 years old, 3 g/ time, 3 times daily. Both groups were treated for 7 d. The clinical efficacy, the time of disappearance of main symptoms and the negative conversion rate of mycoplasma pneumoniae IgM antibody (MP-IgM) were observed in the two groups. Whole blood platelet-lymphocyte ratio (PLR) and serum C-reactive protein (CRP) levels were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 96.55%, significantly higher than that of the control group (86.21%, P < 0.05). In the course of treatment, the disappearance times of main symptoms (fever, cough, asthma, phlegm obstruction, and pulmonary rales) in the treatment group was significantly shorter than that in the control group (P < 0.05). The negative conversion rate of MP-IgM in the treatment group was 89.66%, which was significantly higher than 75.86% in the control group (P < 0.05). After treatment, whole blood PLR and serum CRP levels in two groups were lower than before treatment (P < 0.05). After treatment, the levels of whole blood PLR and serum CRP in treatment group were lower than those in control group (P < 0.05). Conclusion Xiao’er Kechuanling Granules combined with ceftazidime has good clinical efficacy in treatment of mycoplasma pneumonia in children, and can effectively control mycoplasma infection, inhibit inflammation, accelerate the relief of symptoms, which is worthy of clinical application.

R974;R985